Form 4: Exelixis CSO/EVP Dana Aftab Reports Stock Award and 401(k) Holdings

Dana Aftab, CSO/EVP of Discovery & Translational Research at Exelixis, reports the acquisition of stock through restricted stock units (RSUs) and holdings in the company's 401(k) plan.

Summary

• Dana Aftab, CSO/EVP of Discovery & Translational Research at Exelixis, filed a Form 4 detailing changes in beneficial ownership.
• On February 26, 2025, Aftab was granted 49,209 shares of Exelixis common stock in the form of restricted stock units (RSUs).
• These RSUs were granted under the Exelixis, Inc. 2017 Equity Incentive Plan.
• The RSUs vest in four equal installments, starting on May 15, 2026, and then annually on each subsequent May 15th until fully vested.
• Aftab also reported 5,835 shares of common stock held indirectly through the Exelixis, Inc. 401(k) Plan, as of a statement dated February 26, 2024.
• Following these transactions, Aftab beneficially owns 561,117 shares of Exelixis common stock, including shares from RSUs and the 401(k) plan.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting required information about stock ownership. The RSU grant is a positive sign of alignment between the executive and the company's success, but it's a routine event.

Positives

• The grant of RSUs to a key executive like Dana Aftab aligns their interests with the long-term success of Exelixis.
• The vesting schedule of the RSUs encourages continued service and commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements, but the RSU grant suggests an expectation of continued contributions from the executive.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the holdings of company insiders. This filing is typical for executives receiving equity-based compensation.

Comparison to Industry Standards

• RSU grants are a common form of executive compensation in the biotechnology industry, used to align executive incentives with shareholder value.
• Vesting schedules, such as the one described (1/4th annually), are standard practice to ensure long-term commitment.
• Comparing the size of the RSU grant to those of executives at comparable companies (e.g., other oncology-focused biotechs like Array BioPharma (acquired by Pfizer), Loxo Oncology (acquired by Eli Lilly), or Blueprint Medicines) would provide context on its relative value.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive incentive for the executive to drive company performance.
• Employees may see the RSU grant as a sign of the company's commitment to its leadership.

Key Dates